Contrasting Beta Bionics (NASDAQ:BBNX) and Olympus (OTCMKTS:OCPNY)

Olympus (OTCMKTS:OCPNY) and Beta Bionics (NASDAQ:BBNX) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Earnings and Valuation

This table compares Olympus and Beta Bionics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olympus	$7.74 billion	2.99	$1.03 billion	$0.82	21.95
Beta Bionics	$127.27 million	7.16	-$73.20 million	($1.84)	-9.10

Olympus has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than Olympus, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Olympus and Beta Bionics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olympus	0	0	1	0	3.00
Beta Bionics	1	4	9	1	2.67

Beta Bionics has a consensus target price of $23.69, suggesting a potential upside of 41.45%. Given Beta Bionics’ higher possible upside, analysts clearly believe Beta Bionics is more favorable than Olympus.

Profitability

This table compares Olympus and Beta Bionics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Olympus	13.80%	24.30%	9.30%
Beta Bionics	-65.31%	-27.33%	-24.28%

Insider and Institutional Ownership

0.0% of Olympus shares are held by institutional investors. 5.3% of Beta Bionics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

Olympus has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Comparatively, Beta Bionics has a beta of 3.39, suggesting that its share price is 239% more volatile than the S&P 500.

Summary

Olympus beats Beta Bionics on 9 of the 15 factors compared between the two stocks.

About Olympus

Olympus Corp. engages in the manufacture and sale of precision machineries and instruments. It operates through the following segments: Medical, Scientific Solutions, Imaging, and Others. The Medical segment covers digestive, surgical, and ultrasonic endoscopy as well as endoscopic treatment tools. The Scientific Solutions segment manufactures and sells biological and industrial microscopes, industrial endoscopes, and non-destructive testing equipment. The Imaging segment deals with digital cameras and recording devices. The Others segment includes biomaterial manufacturing and sales business. The company was founded by Takeshi Yamashita on October 12, 1919 and is headquartered in Tokyo, Japan.

About Beta Bionics

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.